目的 探討丹杞顆粒聯(lián)合地舒單抗注射液治療骨質(zhì)疏松癥的臨床療效。方法 將黃山首康醫(yī)院在2022年7月—2024年5月收治的92例骨質(zhì)疏松癥患者作為研究對象，按隨機(jī)數(shù)字表法將患者分為對照組和治療組，每組46例。對照組單次皮下注射地舒單抗注射液，每6個月1次。治療組在對照組基礎(chǔ)上溫開水沖服丹杞顆粒，1袋/次，2次/d，3個月為1個療程，持續(xù)治療2個療程。兩組在治療6個月后統(tǒng)計(jì)治療效果。比較兩組的治療效果、全身骨痛程度、骨密度、血清指標(biāo)。結(jié)果 治療組的總有效率為93.48%，對照組的總有效率為78.26%，組間比較差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，兩組的VAS評分均低于治療前（P＜0.05）；治療組的VAS評分低于對照組（P＜0.05）。治療后，兩組的股骨頸、腰椎L₁～L₄、Wards三角區(qū)骨密度高于治療前（P＜0.05）；治療組的股骨頸、腰椎L₁～L₄、Wards三角區(qū)骨密度高于對照組（P＜0.05）。治療后，兩組的血清N端中段骨鈣素（N-MID）、β-Ⅰ型膠原羧基端肽（β-CTX）水平低于治療前，血清I型前膠原羧基端肽（PICP）水平高于治療前（P＜0.05）；治療組的血清N-MID、β-CTX水平低于對照組，血清PICP水平高于對照組（P＜0.05）。治療后，兩組的血清白細(xì)胞介素-17（IL-17）、腫瘤壞死因子-α（TNF-α）水平低于治療前（P＜0.05）；治療組的血清IL-17、TNF-α水平低于對照組（P＜0.05）。結(jié)論 丹杞顆粒聯(lián)合地舒單抗注射液可提高骨質(zhì)疏松癥的臨床療效，減輕全身骨痛程度，提高骨密度，調(diào)節(jié)骨代謝指標(biāo)，減輕炎癥反應(yīng)。

Objective To explore the clinical efficacy of Danqi Granules combined with Denosumab Injection in treatment of osteoporosis. Methods 92 Patients with osteoporosis in Huangshan Shoukang Hospital from July 2022 to May 2024 were selected, and were divided into control group and treatment group by random number table method, with 46 cases in each group. Patients in the control group were sc administered with Denosumab Injection every 6 months. On the basis of the control group, patients in the treatment group were po administered with Danqi Granules with warm water, 1 bag/time, twice daily, for 3 months as one course of treatment, and continued for 2 courses of treatment. After 6 months of treatment, the treatment effects of the two groups were statistically analyzed. Treatment efficacy, degree of systemic bone pain, bone density, and serum indicators between two groups were compared. Results The total effective rate of the treatment group was 93.48%, while the total effective rate of the control group was 78.26%,and the difference between two groups was statistically significant (P < 0.05). After treatment, the VAS scores of both groups were lower than those before treatment (P < 0.05), and the VAS scores of the treatment group were lower than those of the control group (P < 0.05). After treatment, the bone density of the femoral neck, lumbar vertebrae L₁— L₄, and Ward's triangle in both groups was higher than those before treatment (P < 0.05), and the bone densities of the femoral neck, lumbar vertebrae L₁— L₄, and Wards triangle in the treatment group were higher than those in the control group (P < 0.05). After treatment, the levels of serum N-terminal mid segment osteocalcin (N-MID) and β-type I collagen carboxy terminal peptide (β-CTX) in both groups were lower than those before treatment, and the level of serum type I procollagen carboxy terminal peptide (PICP) was higher than those before treatment (P < 0.05). The serum levels of N-MID and β-CTX in the treatment group were lower than those in the control group, but the serum PICP level was higher than that in the control group (P < 0.05). After treatment, the levels of serum interleukin-17 (IL-17) and tumor necrosis factor-α (TNF-α) in both groups were lower than those before treatment (P < 0.05), and the serum levels of IL-17 and TNF-α in the treatment group were lower than those in the control group (P < 0.05). Conclusion Danqi Granules combined with Denosumab Injection can improve the clinical efficacy of osteoporosis, reduce systemic bone pain, increase bone density, regulate bone metabolism indicators, and alleviate inflammatory reactions.

R982